Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novo Nordisk's semaglutide misses in closely-watched Alzheimer’s trials
Novo Nordisk’s bet on semaglutide in Alzheimer’s disease was always a long shot, and like most long shots, it has missed the mark. The GLP-1 agonist failed to delay dis...
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page